Massachusetts Financial Services Co. MA Sells 79,145 Shares of Qiagen (NYSE:QGEN)

Massachusetts Financial Services Co. MA reduced its position in shares of Qiagen (NYSE:QGEN) by 0.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,117,292 shares of the company’s stock after selling 79,145 shares during the period. Massachusetts Financial Services Co. MA owned approximately 10.13% of Qiagen worth $1,053,455,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Nuance Investments LLC grew its stake in Qiagen by 17.3% in the 2nd quarter. Nuance Investments LLC now owns 5,271,494 shares of the company’s stock worth $216,606,000 after buying an additional 778,005 shares in the last quarter. Earnest Partners LLC grew its position in Qiagen by 11.1% in the second quarter. Earnest Partners LLC now owns 3,807,284 shares of the company’s stock worth $156,441,000 after acquiring an additional 379,679 shares in the last quarter. DekaBank Deutsche Girozentrale increased its stake in Qiagen by 12.2% in the second quarter. DekaBank Deutsche Girozentrale now owns 3,248,354 shares of the company’s stock valued at $133,292,000 after acquiring an additional 353,280 shares during the last quarter. Victory Capital Management Inc. raised its position in Qiagen by 62.6% during the third quarter. Victory Capital Management Inc. now owns 2,574,705 shares of the company’s stock valued at $117,329,000 after purchasing an additional 991,325 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in Qiagen by 16.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 2,320,088 shares of the company’s stock worth $105,726,000 after purchasing an additional 324,417 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Stock Up 3.2 %

QGEN stock opened at $42.11 on Thursday. The business’s 50-day moving average is $43.57 and its two-hundred day moving average is $43.73. Qiagen has a fifty-two week low of $39.03 and a fifty-two week high of $47.44. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17. The company has a market cap of $9.61 billion, a price-to-earnings ratio of 107.97, a P/E/G ratio of 3.16 and a beta of 0.41.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on QGEN shares. Robert W. Baird upped their price target on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. HSBC lowered shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target for the company. in a report on Thursday, October 17th. Finally, Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a research report on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $50.88.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.